RPCEC00000349已完成1 期
Phase I study, open, adaptive and monocentric, to evaluate the safety, reactogenicity and explore the immunogenicity of the prophylactic vaccine candidate FINLAY-FR-1A against SARS-CoV-2, in convalescent of COVID-19. - SOBERANA 01B
Finlay Vaccine Institute (IFV)0 个研究点目标入组 30 人开始时间: 2021年1月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
入排标准
- 年龄范围
- 19 years 至 59 years（—）
- 性别
- All
入选标准
- •1. Subjects who give their written informed consent to participate in the study.
- •2. Subjects aged between 19 and 59 years.
- •3. Body mass index between 18.5 and 29.9 kg / m2.
- •4. Women of childbearing potential use safe contraceptive methods during the study.
排除标准
- •1. Subjects with a history of COVID-19 who meet any of the following criteria:
- •a) Current history of infection or having received a medical discharge for SARS-CoV 2 during the 2 months prior to recruitment.
- •b) History of severe clinical picture due to COVID-19, according to your medical history or obtained during the medical interview.
- •c) Baseline antibody levels showing a =60% inhibition of RBD binding to its receptor.
- •2. Subjects with acute febrile or infectious disease in the 7 days prior to the administration of the vaccine or at the time of its application. 3. Subjects with antimicrobial treatment or sustained treatment with NSAIDs in the 7 days prior to the administration of the vaccine.
- •4. Subjects with chronic non-communicable diseases that are NOT controlled, according to clinical or laboratory criteria established for each entity in the Cuban medical standards (Ex: bronchial asthma, chronic obstructive pulmonary disease, ischemic heart disease, arterial hypertension, diabetes mellitus, thyroid diseases , neurological, hemolymphopoietic system, liver failure, kidney failure, psychiatric illness at a psychotic level, among others).
- •5. Subjects with congenital or acquired immune system disease.
- •6. Subjects with a history of neoplastic disease.
- •7. Subjects with a history of substance abuse in the past 30 days or substance addictive illness, except smoking.
- •8. Subjects with diminished mental faculties.
- •9. Subjects with a history of severe allergic disease (anaphylactic shock, angioneurotic edema, glottis edema, severe urticaria).
- •10. Subjects with a history of hypersensitivity to thiomersal.
- •11. Participation in another clinical trial of preventive or therapeutic intervention in the last 3 months.
- •12. Application of another vaccine in the last 30 days.
- •13. Treatment with immunomodulators in the last 30 days, eg; steroids (except for the occasional use of topical or inhaled steroids), cytostatics, interferon, immunoferon, transfer factor, monoclonal antibodies, biomodulin T, any ganmaglobulin, levamisole, heberferon, thymosin) or those who, due to their underlying disease, require treatment immunomodulator, which may coincide during the development of the study.
- •14. History of having received a blood transfusion or blood products in the last 3 months.
- •15. Subjects with difficulties in attending the planned follow-up consultations.
- •16. Splenectomy or splenic dysfunction.
- •17. Pregnancy, puerperium or lactation.
- •18. Subjects with tattoos in the deltoid region of both arms. 19. Subjects with positive results for: antibodies against HIV1 + 2, antibodies against hepatitis C, surface antigen of the hepatitis B virus and VDRL serology.
研究者
相似试验
已完成
1 期
SOBERANA 02Prevention of COVID-19COVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000340Finlay Vaccine Institute (IFV)40
已完成
1 期
A phase I, single-centre, open study to assess the pharmacokinetic profile and safety of a 100 mg Clindamycin Hydrochloride Vaginal Insert (CHVI) in healthy femalesAcute vaginitisBacterial vaginosisUrological and Genital DiseasesISRCTN15152571Controlled Therapeutics (Scotland) Ltd (UK)10
招募中
1 期
A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-Linked Chronic Granulomatous DiseaseTreatment of X-linked Chronic Granulomatous DiseaseMedDRA version: 20.0Level: PTClassification code: 10008906Term: Chronic granulomatous disease Class: 100000004850CTIS2024-512790-27-00Genethon5
进行中（未招募）
1 期
The study to assess the efficacy and safety of new Interferon alpha-2b formulation in patients with primary myelofibrosisPrimary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteriaMedDRA version: 17.0 Level: LLT Classification code 10053134 Term: Osteomyelofibrosis System Organ Class: 100000004864EUCTR2014-001367-13-ATMedizinische Universtät Wien, Universitätsklinik für Innere Medizin I24
已完成
1 期
Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe HemophiliaSevere HemophiliaNCT04878731Pfizer6